About Xcellerex

Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized.

Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. The Xcellerex platform transforms biomanufacturing economics by enabling:

Faster deployment of new manufacturing capacity: 12-18 months vs. 3-5 years.

Reduced capital investment: Typical savings of 50% to 70% compared to conventional approaches.

Unmatched flexibility: Modular microenvironment approach enables fast, low-cost redeployment for multi-drug production.

Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of single-use bioreactors, PDMax^TM high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform.

Further, Xcellerex uses its platform as the foundation for building its own portfolio of proprietary biotherapeutics and vaccines. By leveraging the company’s inhouse process development and manufacturing expertise, Xcellerex is able to commercialize biomolecules that may not achieve financial viability using conventional approaches.